Business Daily Media

Men's Weekly

.

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan

  • Written by ACN Newswire - Press Releases

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan

TOKYO, Nov 18, 2020 - (JCN Newswire) - Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18 for the treatment of rheumatoid arthritis (RA), with prior

Read more //?#

Deputy Launches Payroll in Australia: Purpose Built for Shift-Based Businesses

Deputy, the global people platform purpose-built for shift work, officially launched Deputy Payroll in Australia today — a seamless experience desig...

How Notion is Addressing Australia's Tech Bloat and Productivity Challenges

In Australia's rapidly evolving digital landscape, businesses are facing an unexpected challenge : tech bloat. This phenomenon is causing a signific...

Konica Minolta Australia partners with Box to drive Intelligent Content Management

Konica Minolta Australia has announced a strategic partnership with Box, the leader in Intelligent Content Management, to deliver a transformative...

TP Leverages AI for Accent-Translation to Improve Customer Engagement

Global digital business services provider Teleperformance (TP) is leveraging AI voice technology to improve communication between customers and se...

The quiet majority: why marketers need to cater to low intent shoppers

When shoppers are browsing online, whether for a new phone, holiday, or pair of shoes, they usually know exactly where they stand. Sometimes they’...

Lack of Salary Transparency is Costing Businesses Top Talent, Says Recruiters

As end-of-financial-year reviews approach, new research reveals a growing disconnect between Australian employers and employees on the issue of sa...

Sell by LayBy